China is today promoting the development of biotechnology by constructing the Biological Technology Cooperation Industrial Zone, together with Cuba.
Municipal government authorities from Changchun, in the province of Jilin, and representatives of Cuba’s BioCubaFarma Enterprise Group, reaffirmed their interest in defining joint actions as part of this strategic alliance, PL reported.
Since 2003, Jilin has been home to the Changchun Heber Biological Technology joint venture, whose main objective is the manufacture of biotechnology products with Cuban cooperation.
Moreover, in May this year a Framework Agreement for the joint construction of the Cuba-China Biological Technology Cooperation Industrial Zone was signed.
Cuban biotechnology already enjoys a presence in the Asian nation through the joint ventures Biotech, located in the Beijing Special Development Zone and the abovementioned Chang Heber, in the north of the country.
The Biotech enterprise is responsible for producing and marketing the humanized monoclonal antibody Nimotuzumab-R3, obtained by Cuba and used in combination with chemotherapy and radiotherapy for the treatment of advanced tumors.
